The Alzheimer’s disease (AD) market today comprises a handful of symptomatic options that offer only modest efficacy of limited duration, leaving ample room for novel, more-effective alternatives…
The type 2 diabetes therapy market will steadily expand over our 2017-2027 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in…
MARKET OUTLOOK The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The anticipated entry of first-in-UC oral therapies for the moderate to severe population,…
Market Outlook: Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses and drug-treatment options. MabThera remains at the heart of NHL treatment, and recent…
Immune checkpoint inhibitors have revolutionized the treatment of multiple oncology indications, but the high costs associated with these agents present significant challenges for payers. The…
Overall, the renal anemia therapy market will expand over the 2017-2027 study period, fueled by the increasing prevalence of this complication of chronic kidney disease and the emergence of a novel…
PsA, a disease characterized by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly understood, underdiagnosed, and undertreated. Nevertheless, TNF…
Market Outlook This report examines the market access factors that influence the success of therapies for chronic heart failure (CHF), with a special focus on payers’ and cardiologists’…
Market Outlook Biomarker-driven prescribing continues to play an increasingly prominent role in key oncology indications. Biomarkers play an important role and are well-entrenched in indications…
MARKET OUTLOOK The Crohn’s disease(CD) therapy market will continue to evolve over the next decade. The well-established TNF-α inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s…
Recent launches of trastuzumab biosimilars (Celltrion/Mundipharma’s Herzuma, Samsung Bioepis/Merck & Co.’s Ontruzant, Amgen/Allergan’s Kanjinti) have expanded the biosimilar sector of the…
MARKET OUTLOOK The human immunodeficiency virus (HIV) therapy market is dynamic and growing as many effective antiretroviral therapies (ARTs), such as Gilead’s Biktarvy, continue to launch,…
MARKET OUTLOOK The human immunodeficiency virus (HIV) therapy market is dynamic and growing as many effective antiretroviral therapies (ARTs), such as Gilead’s Biktarvy, continue to launch,…
MARKET OUTLOOK SLE is an autoimmune disease that can manifest in many different organs, including the kidneys. Renal inflammation associated with SLE, also known as lupus nephritis, is among the…
MARKET OUTLOOK The hospital-treated gram-negative infection (GNI) therapy market is dominated by highly effective, generically available antibiotics. However, the rising prevalence of multidrug-…